Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
about
Recovery of endocrine function after islet and pancreas transplantationExtent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus.Meal feeding improves oral glucose tolerance in male rats and causes adaptations in postprandial islet hormone secretion that are independent of plasma incretins or glycemia.Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells.Possible contribution of taurine to distorted glucagon secretion in intra-islet insulin deficiency: a metabolome analysis using a novel α-cell model of insulin-deficient diabetes.How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited.Establishment of a Refined Oral Glucose Tolerance Test in Pigs, and Assessment of Insulin, Glucagon and Glucagon-Like Peptide-1 ResponsesGlycemic variability in patients with Wolfram syndrome is lower than in type 1 diabetes.TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes.Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetesUCP2 is highly expressed in pancreatic alpha-cells and influences secretion and survival.Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocolDynamic changes in pancreatic endocrine cell abundance, distribution, and function in antigen-induced and spontaneous autoimmune diabetes.Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and PolymorphismsDiminished adenosine A1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes.Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis.Inhibiting or antagonizing glucagon: making progress in diabetes care.Role of histamine H3 receptor in glucagon-secreting αTC1.6 cellsThe New Biology and Pharmacology of Glucagon.Cell type-specific activation of metabolism reveals that beta-cell secretion suppresses glucagon release from alpha-cells in rat pancreatic islets.Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes.Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction.Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.Assessment of Beta Cell Mass and Function by AIRmax and IVGTT in High Risk Subjects for Type 1 Diabetes.[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].Targeting postprandial glycaemia in children with diabetes: Opportunities and challenges.Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls.The physiology of incretin hormones and the basis for DPP-4 inhibitors.
P2860
Q26822596-4DD350FA-E87E-4BC9-B5B7-7F694E9309B9Q33312930-2313BC24-93D2-4BFB-9FBC-A83AD8EFB6FEQ34439517-42CB0BB7-527E-45FF-AA95-7F86FE036424Q34981767-3FFF4A75-9A3D-4868-92F1-21121BCA722EQ35417285-D7D89D5F-3C71-49F5-A70D-9818FD85A5D8Q35796906-2B64FA2E-CC84-4C97-B1EE-4AECE0083B1DQ35918025-1C778DB3-1B44-4172-A8D1-2E6B5E6E341BQ36234364-5A33A99B-51C7-4ABB-AEBE-D26FB473506AQ36562549-D43508B9-A1E4-4062-8678-BEF6109F1FA2Q36693199-82A444FB-7401-467E-8334-BBAC5D4CC9D2Q36906207-783A9B4D-E99A-4EFB-89C5-6DE00EC48871Q36954492-1B748D09-A9F4-4326-913C-8AB843300631Q37031038-C26C7999-1B0A-4D37-B46F-54C153339050Q37163562-DAB39E2F-0D79-4EC0-AAE0-A9A1B0FED69EQ37200819-0CC424BF-F4DB-47C9-90F5-2AFA9664A68AQ37333575-BF320771-5877-4478-B35B-69AB33464631Q37381194-93FE80B1-FF1B-4259-921B-D46080F17F79Q38024321-11D30688-F12B-4CA1-9261-D74694DA6BD1Q38200560-5120D7E9-5AED-45D3-B30F-DF8ED25A001FQ38449296-4006908C-0CFA-49F2-A84A-047D1F8A4673Q38909178-4F29C4B5-F68E-4381-A581-23626DE433F3Q38919742-1D7C3BAB-47FA-4236-8416-9681DDE17320Q40368133-DB360243-12B0-4B31-84AC-C7393D04C7FEQ42008289-A70A2E47-AE32-4301-8E40-2286BF27E2F2Q43183447-FBBD90B2-DCEB-4C06-A234-55DDF9A845C6Q43225003-7CB02A38-EDD8-4C37-A989-84F9752A2977Q44286265-F1D2407C-1A4E-4CD1-B13B-4CB83087DA46Q45070289-97B503F4-8F47-4EFB-9B93-6334E460DEBEQ46625434-1969DB2E-0C14-474E-B813-D9E143794DB8Q48123950-1466FF3D-0814-48B5-8734-7A21AFBA6D43Q51319337-4F37357E-300A-4CFD-869B-91707EA5051CQ53242373-BC3FE69D-D38A-49A1-B7AA-7EBAA3480C40
P2860
Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Impaired beta-cell function, i ...... o have normal fasting glucose.
@en
Impaired beta-cell function, i ...... o have normal fasting glucose.
@nl
type
label
Impaired beta-cell function, i ...... o have normal fasting glucose.
@en
Impaired beta-cell function, i ...... o have normal fasting glucose.
@nl
prefLabel
Impaired beta-cell function, i ...... o have normal fasting glucose.
@en
Impaired beta-cell function, i ...... o have normal fasting glucose.
@nl
P2093
P1433
P1476
Impaired beta-cell function, i ...... o have normal fasting glucose.
@en
P2093
Carla J Greenbaum
David A D'Alessio
Ronald L Prigeon
P304
P356
10.2337/DIABETES.51.4.951
P407
P577
2002-04-01T00:00:00Z